The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation

Cell Communication and Signaling

Volumn 15, Issue 1, 2017, Pages

  Wolff, Florian ^a   Leisch, Michael ^b   Greil, Richard ^b,c,d   Risch, Angela ^a,d   Pleyer, Lisa ^b,c,d  

^a UNIVERSITY OF SALZBURG   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c III rd Medical Department with Hematology Medical Oncology Hemostasis Rheumatology and Infectious Diseases Oncologic Center Center for Clinical Cancer and Immunology Trials   (Austria)

^d Salzburg Cancer Research Institute   (Austria)

Author keywords

Acute myeloid leukemia; Azacitidine; Cancer; Decitabine; DNA methylation; Endogenous retroviral elements; Hypomethylating agents; Immune checkpoint blockade; Immune checkpoint inhibitors; Tumor microenvironment

Indexed keywords

ALPHA INTERFERON; ATEZOLIZUMAB; AVELUMAB; AZACITIDINE; B7 ANTIGEN; BETA INTERFERON; CD28 ANTIGEN; CD86 ANTIGEN; CXCL9 CHEMOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DECITABINE; DURVALUMAB; ENTINOSTAT; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GUADECITABINE; INTERFERON; INTERLEUKIN 28A; INTERLEUKIN 28B; INTERLEUKIN 29; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; ROMIDEPSIN; TETRAHYDROURIDINE; TICILIMUMAB; TUMOR ANTIGEN;

ACUTE MYELOID LEUKEMIA; ANTIGEN PRESENTATION; BREAST CANCER; CHRONIC MYELOMONOCYTIC LEUKEMIA; COLORECTAL CANCER; DEFENSE MECHANISM; DNA STRUCTURE; ENDOGENOUS RETROVIRUS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE EXPRESSION; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER; INFLAMMATION; LONG INTERSPERSED ELEMENT; METASTATIC MELANOMA; MYELODYSPLASTIC SYNDROME; NON SMALL CELL LUNG CANCER; OVARY CANCER; PERITONEUM CANCER; PRIMARY PERITONEAL CANCER; PROMOTER REGION; RETROPOSON; REVIEW; SHORT INTERSPERSED ELEMENT; SIGNAL TRANSDUCTION; TUMOR ESCAPE; UPREGULATION; UTERINE TUBE TUMOR; ANIMAL; DNA METHYLATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNE EVASION; IMMUNITY; IMMUNOLOGY; MOLECULAR MIMICRY; NEOPLASM;

ANIMALS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNE EVASION; IMMUNITY; MOLECULAR MIMICRY; NEOPLASMS;

EID: 85016494454     PISSN: None     EISSN: 1478811X     Source Type: Journal    
DOI: 10.1186/s12964-017-0168-z     Document Type: Review

References (121)

1. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012;13:484-92. doi:10.1038/nrg3230.
2. Lister R, Ecker JR. Finding the fifth base: genome-wide sequencing of cytosine methylation. Genome Res. 2009;19:959-66. doi:10.1101/gr.083451.108.
3. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011;11:726-34. doi:10.1038/nrc3130.
4. Torres IO, Fujimori DG. Functional coupling between writers, erasers and readers of histone and DNA methylation. Curr Opin Struct Biol. 2015;35:68-75. doi:10.1016/j.sbi.2015.09.007.
5. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31:27-36. doi:10.1093/carcin/bgp220.
6. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415-28. doi:10.1038/nrg816.
7. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science. 2003;300:455. doi:10.1126/science.1083557.
8. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol. 2005;2 Suppl 1:S4-11. doi:10.1038/ncponc0354.
9. Jankowska AM, Millward CL, Caldwell CW. The potential of DNA modifications as biomarkers and therapeutic targets in oncology. Expert Rev Mol Diagn. 2015;15:1325-37. doi:10.1586/14737159.2015.1084229.
10. Khakpour G, Pooladi A, Izadi P, Noruzinia M, Tavakkoly Bazzaz J. DNA methylation as a promising landscape: A simple blood test for breast cancer prediction. Tumour Biol. 2015;36:4905-12. doi:10.1007/s13277-015-3567-z.
11. Ansari J, Shackelford RE, El-Osta H. Epigenetics in non-small cell lung cancer: from basics to therapeutics. Transl Lung Cancer Res. 2016;5:155-71. doi:10.21037/tlcr.2016.02.02.
12. Figueroa ME, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010;17:13-27. doi:10.1016/j.ccr.2009.11.020.
13. Bullinger L, et al. Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. Blood. 2010;115:636-42. doi:10.1182/blood-2009-03-211003.
14. Pleyer L, Greil R. Digging deep into “dirty” drugs - modulation of the methylation machinery. Drug Metab Rev. 2015;47:252-79. doi:10.3109/03602532.2014.995379.
15. Santi DV, Norment A, Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci U S A. 1984;81:6993-7.
16. Fenaux P, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223-32. doi:10.1016/S1470-2045(09)70003-8.
17. Fenaux P, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28:562-9. doi:10.1200/JCO.2009.23.8329.
18. Dombret H, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126:291-9. doi:10.1182/blood-2015-01-621664.
19. Kantarjian HM, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30:2670-7. doi:10.1200/JCO.2011.38.9429.
20. Garcia-Manero G, et al. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. J Clin Oncol. 2013;31:2548-53. doi:10.1200/JCO.2012.44.6823.
21. Pleyer L, et al. Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. J Hematol Oncol. 2013;6:32. doi:10.1186/1756-8722-6-32.
22. Pleyer L, et al. Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. Ann Hematol. 2014;93:1825-38. doi:10.1007/s00277-014-2126-9.
23. Pleyer L, et al. Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. Leuk Res. 2014;38:475-83. doi:10.1016/j.leukres.2014.01.006.
24. Pleyer L, et al. Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications. J Hematol Oncol. 2016;9:39. doi:10.1186/s13045-016-0263-4.
25. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: acute myeloid leukemia guidelines version 2. 2016.
26. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: myelodysplastic syndromes guidelines. 2016.
27. Bender CM, Pao MM, Jones PA. Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res. 1998;58:95-101.
28. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21:103-7. doi:10.1038/5047.
29. Karpf AR, Jones DA. Reactivating the expression of methylation silenced genes in human cancer. Oncogene. 2002;21:5496-503. doi:10.1038/sj.onc.1205602.
30. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell. 1980;20:85-93.
31. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med. 2001;134:573-86.
32. Issa JP, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004;103:1635-40. doi:10.1182/blood-2003-03-0687.
33. Kantarjian H, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109:52-7. doi:10.1182/blood-2006-05-021162.
34. Kantarjian H, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794-803. doi:10.1002/cncr.21792.
35. Lubbert M, et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol. 2001;114:349-57.
36. Wijermans P, et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000;18:956-62.
37. Cui J, Chen Y, Wang HY, Wang RF. Mechanisms and pathways of innate immune activation and regulation in health and cancer. Hum Vaccin Immunother. 2014;10:3270-85. doi:10.4161/21645515.2014.979640.
38. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11:373-84. doi:10.1038/ni.1863.
39. Pichlmair A, et al. Activation of MDA5 requires higher-order RNA structures generated during virus infection. J Virol. 2009;83:10761-9. doi:10.1128/JVI.00770-09.
40. Heil F, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004;303:1526-9. doi:10.1126/science.1093620.
41. Goubau D, Deddouche S, Reis e Sousa C. Cytosolic sensing of viruses. Immunity. 2013;38:855-69. doi:10.1016/j.immuni.2013.05.007.
42. Seth RB, Sun L, Ea CK, Chen ZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell. 2005;122:669-82. doi:10.1016/j.cell.2005.08.012.
43. Barbalat R, Ewald SE, Mouchess ML, Barton GM. Nucleic acid recognition by the innate immune system. Annu Rev Immunol. 2011;29:185-214. doi:10.1146/annurev-immunol-031210-101340.
44. Sun Q, et al. The specific and essential role of MAVS in antiviral innate immune responses. Immunity. 2006;24:633-42. doi:10.1016/j.immuni.2006.04.004.
45. Zhou Z, et al. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol. 2007;81:7749-58. doi:10.1128/JVI.02438-06.
46. Donnelly RP, Kotenko SV. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res. 2010;30:555-64. doi:10.1089/jir.2010.0078.
47. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14:36-49. doi:10.1038/nri3581.
48. Schoggins JW, Rice CM. Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol. 2011;1:519-25. doi:10.1016/j.coviro.2011.10.008.
49. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015;15:405-14. doi:10.1038/nri3845.
50. Lander ES, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860-921. doi:10.1038/35057062.
51. Doucet AJ, et al. Characterization of LINE-1 ribonucleoprotein particles. PLoS Genet. 2010; 6. doi:10.1371/journal.pgen.1001150.
52. Cordaux R, Batzer MA. The impact of retrotransposons on human genome evolution. Nat Rev Genet. 2009;10:691-703. doi:10.1038/nrg2640.
53. McCarthy EM, McDonald JF. Long terminal repeat retrotransposons of Mus musculus. Genome Biol. 2004;5:R14. doi:10.1186/gb-2004-5-3-r14.
54. Kim FJ, Battini JL, Manel N, Sitbon M. Emergence of vertebrate retroviruses and envelope capture. Virology. 2004;318:183-91. doi:10.1016/j.virol.2003.09.026.
55. Wicker T, et al. A unified classification system for eukaryotic transposable elements. Nat Rev Genet. 2007;8:973-82. doi:10.1038/nrg2165.
56. Khodosevich K, Lebedev Y, Sverdlov E. Endogenous retroviruses and human evolution. Comp Funct Genomics. 2002;3:494-8. doi:10.1002/cfg.216.
57. Belshaw R, et al. Long-term reinfection of the human genome by endogenous retroviruses. Proc Natl Acad Sci U S A. 2004;101:4894-9. doi:10.1073/pnas.0307800101.
58. Kassiotis G, Stoye JP. Immune responses to endogenous retroelements: taking the bad with the good. Nat Rev Immunol. 2016;16:207-19. doi:10.1038/nri.2016.27.
59. Oliver KR, Greene WK. Mobile DNA and the TE-Thrust hypothesis: supporting evidence from the primates. Mob DNA. 2011;2:8. doi:10.1186/1759-8753-2-8.
60. Medstrand P, et al. Impact of transposable elements on the evolution of mammalian gene regulation. Cytogenet Genome Res. 2005;110:342-52. doi:10.1159/000084966.
61. Blond JL, et al. An envelope glycoprotein of the human endogenous retrovirus HERV-W is expressed in the human placenta and fuses cells expressing the type D mammalian retrovirus receptor. J Virol. 2000;74:3321-9.
62. Dupressoir A, et al. Syncytin-A knockout mice demonstrate the critical role in placentation of a fusogenic, endogenous retrovirus-derived, envelope gene. Proc Natl Acad Sci U S A. 2009;106:12127-32. doi:10.1073/pnas.0902925106.
63. Goke J, Ng HH. CTRL+INSERT: retrotransposons and their contribution to regulation and innovation of the transcriptome. EMBO Rep. 2016;17:1131-44. doi:10.15252/embr.201642743.
64. Chuong EB, Elde NC, Feschotte C. Regulatory evolution of innate immunity through co-option of endogenous retroviruses. Science. 2016;351:1083-7. doi:10.1126/science.aad5497.
65. Chuong EB, Elde NC, Feschotte C. Regulatory activities of transposable elements: from conflicts to benefits. Nat Rev Genet. 2016. doi:10.1038/nrg.2016.139.
66. Lynch VJ. GENETICS. A copy-and-paste gene regulatory network. Science. 2016;351:1029-30. doi:10.1126/science.aaf2977.
67. Sundaram V, et al. Widespread contribution of transposable elements to the innovation of gene regulatory networks. Genome Res. 2014;24:1963-76. doi:10.1101/gr.168872.113.
68. Santangelo AM, et al. Ancient exaptation of a CORE-SINE retroposon into a highly conserved mammalian neuronal enhancer of the proopiomelanocortin gene. PLoS Genet. 2007;3:1813-26. doi:10.1371/journal.pgen.0030166.
69. Liang KH, Yeh CT. A gene expression restriction network mediated by sense and antisense Alu sequences located on protein-coding messenger RNAs. BMC Genomics. 2013;14:325. doi:10.1186/1471-2164-14-325.
70. Chueh AC, Northrop EL, Brettingham-Moore KH, Choo KH, Wong LH. LINE retrotransposon RNA is an essential structural and functional epigenetic component of a core neocentromeric chromatin. PLoS Genet. 2009;5:e1000354. doi:10.1371/journal.pgen.1000354.
71. Rowe HM, Trono D. Dynamic control of endogenous retroviruses during development. Virology. 2011;411:273-87. doi:10.1016/j.virol.2010.12.007.
72. Nelson HH, Marsit CJ, Kelsey KT. Global methylation in exposure biology and translational medical science. Environ Health Perspect. 2011;119:1528-33. doi:10.1289/ehp.1103423.
73. Weisenberger DJ, et al. Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res. 2005;33:6823-36. doi:10.1093/nar/gki987.
74. Tabish AM, et al. Assessment of Changes in Global DNA Methylation Levels by Pyrosequencing(R) of Repetitive Elements. Methods Mol Biol. 2015;1315:201-7. doi:10.1007/978-1-4939-2715-9_15.
75. Lee E, et al. Landscape of somatic retrotransposition in human cancers. Science. 2012;337:967-71. doi:10.1126/science.1222077.
76. Szpakowski S, et al. Loss of epigenetic silencing in tumors preferentially affects primate-specific retroelements. Gene. 2009;448:151-67. doi:10.1016/j.gene.2009.08.006.
77. Christensen T. Human endogenous retroviruses in neurologic disease. APMIS. 2016;124:116-26. doi:10.1111/apm.12486.
78. Strick R, Strissel PL, Baylin SB, Chiappinelli KB. Unraveling the molecular pathways of DNA-methylation inhibitors: human endogenous retroviruses induce the innate immune response in tumors. Oncoimmunology. 2016;5:e1122160. doi:10.1080/2162402X.2015.1122160.
79. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5:375-86. doi:10.1038/nri1604.
80. Almstedt M, et al. The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res. 2010;34:899-905. doi:10.1016/j.leukres.2010.02.004.
81. Atanackovic D, et al. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia. Am J Hematol. 2011;86:918-22. doi:10.1002/ajh.22141.
82. Guo ZS, et al. De novo induction of a cancer/testis antigen by 5-aza-2′-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res. 2006;66:1105-13. doi:10.1158/0008-5472.CAN-05-3020.
83. Weber J, et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine. Cancer Res. 1994;54:1766-71.
84. Dubovsky JA, et al. Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clin Cancer Res. 2009;15:3406-15. doi:10.1158/1078-0432.CCR-08-2099.
85. De Smet C, Lurquin C, Lethe B, Martelange V, Boon T. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol. 1999;19:7327-35.
86. Goodyear O, et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood. 2010;116:1908-18. doi:10.1182/blood-2009-11-249474.
87. Fonsatti E, et al. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2′-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin Cancer Res. 2007;13:3333-8. doi:10.1158/1078-0432.CCR-06-3091.
88. Yao Y, et al. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine. PLoS One. 2013;8:e70522. doi:10.1371/journal.pone.0070522.
89. Tsai HC, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 2012;21:430-46. doi:10.1016/j.ccr.2011.12.029.
90. Wrangle J, et al. Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget. 2013;4:2067-79. doi:10.18632/oncotarget.1542.
91. Li H, et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget. 2014;5:587-98. doi:10.18632/oncotarget.1782.
92. Chiappinelli KB, et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 2015;162:974-86. doi:10.1016/j.cell.2015.07.011.
93. Roulois D, et al. DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. Cell. 2015;162:961-73. doi:10.1016/j.cell.2015.07.056.
94. Connolly RMZC, Zhang Z, Rudek MA, Jeter SC, Slater S, Powers P, Wolff AC, Fetting J, Brufsky AM, Piekarz R, Ahuja N, Somlo G, Garcia AA, Baylin SB, Davidson NE, Stearns V. A Phase 2 Study Investigating the Safety, Efficacy and Surrogate Biomarkers of Response of 5-Azacitidine (5-AZA) and Entinostat (MS-275) in Patients with Advanced Breast Cancer. AACR Annual Meeting 2013, Washington, DC. 2013 (Abs 4666); 2013.
95. Peng D, et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature. 2015;527:249-53. doi:10.1038/nature15520.
96. Nagarsheth N, et al. PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer. Cancer Res. 2016;76:275-82. doi:10.1158/0008-5472.CAN-15-1938.
97. Musha H, et al. Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma. Int J Cancer. 2005;116:949-56. doi:10.1002/ijc.21135.
98. Son DS, Parl AK, Rice VM, Khabele D. Keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) chemokines and pro-inflammatory chemokine networks in mouse and human ovarian epithelial cancer cells. Cancer Biol Ther. 2007;6:1302-12.
99. Ohtani H, Jin Z, Takegawa S, Nakayama T, Yoshie O. Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+ T cells in lymphocyte-rich gastric carcinoma. J Pathol. 2009;217:21-31. doi:10.1002/path.2448.
100. Parker BS, Rautela J, Hertzog PJ. Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer. 2016;16:131-44. doi:10.1038/nrc.2016.14.
101. Stengel S, Fiebig U, Kurth R, Denner J. Regulation of human endogenous retrovirus-K expression in melanomas by CpG methylation. Genes Chromosomes Cancer. 2010;49:401-11. doi:10.1002/gcc.20751.
102. Laska MJ, Nissen KK, Nexo BA. (Some) cellular mechanisms influencing the transcription of human endogenous retrovirus, HERV-Fc1. PLoS One. 2013;8:e53895. doi:10.1371/journal.pone.0053895.
103. Strissel PL, et al. Reactivation of codogenic endogenous retroviral (ERV) envelope genes in human endometrial carcinoma and prestages: Emergence of new molecular targets. Oncotarget. 2012;3:1204-19. doi:10.18632/oncotarget.679.
104. Snyder A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189-99. doi:10.1056/NEJMoa1406498.
105. Weiss RA. Human endogenous retroviruses: friend or foe? APMIS. 2016;124:4-10. doi:10.1111/apm.12476.
106. Pitt JM, et al. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. Immunity. 2016;44:1255-69. doi:10.1016/j.immuni.2016.06.001.
107. Schadendorf D, et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol. 2015;33:1889-94. doi:10.1200/JCO.2014.56.2736.
108. Royal RE, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33:828-33. doi:10.1097/CJI.0b013e3181eec14c.
109. Brahmer JR, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-65. doi:10.1056/NEJMoa1200694.
110. Diamond MS, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011;208:1989-2003. doi:10.1084/jem.20101158.
111. Fuertes MB, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha} + dendritic cells. J Exp Med. 2011;208:2005-16. doi:10.1084/jem.20101159.
112. Tang H, et al. Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. Cancer Cell. 2016;29:285-96. doi:10.1016/j.ccell.2016.02.004.
113. Bald T, et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov. 2014;4:674-87. doi:10.1158/2159-8290.CD-13-0458.
114. Yang H, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28:1280-8. doi:10.1038/leu.2013.355.
115. Orskov AD, et al. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation. Oncotarget. 2015;6:9612-26. doi:10.18632/oncotarget.3324.
116. Greil R, Hutterer E, Hartmann TN, Pleyer L. Reactivation of dormant anti-tumor immunity - A clinical perspective of therapeutic immune checkpoint modulation. Cell Commun Signal. 2016;15:14.
117. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med. 1996;183:2541-50.
118. Wang LX, et al. Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses. PLoS One. 2013;8:e62924. doi:10.1371/journal.pone.0062924.
119. Liu M, et al. Vitamin C increases viral mimicry induced by 5-aza-2′-deoxycytidine. Proc Natl Acad Sci U S A. 2016;113:10238-44. doi:10.1073/pnas.1612262113.
120. Von Hoff DD, Slavik M, Muggia FM. 5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia. Ann Intern Med. 1976;85:237-45.
121. Sistigu A, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014;20:1301-9. doi:10.1038/nm.3708.